Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis

Arthritis and Rheumatology

Volumn 68, Issue 11, 2016, Pages 2784-2794

  Truchetet, Marie Elise ^a   Demoures, Béatrice ^a   Eduardo Guimaraes, Jorge ^b   Bertrand, Anne ^c   Laurent, Paôline ^a   Jolivel, Valérie ^a   Douchet, Isabelle ^a   Jacquemin, Clément ^a   Khoryati, Liliane ^a   Duffau, Pierre ^a   Lazaro, Estibaliz ^a   Richez, Christophe ^a   Seneschal, Julien ^c   Doutre, Marie Sylvie ^c   Pellegrin, Jean Luc ^c   Constans, Joël ^c   Schaeverbeke, Thierry ^c   Blanco, Patrick ^a   Contin Bordes, Cécile ^a  

^a CNRS Bordeaux Segalen University   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c University Hospital Bordeaux   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SEROTONIN; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR; CYTOKINE; IL1B PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FINGER ULCER; FREQUENCY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASCULAR FIBROSIS; CASE CONTROL STUDY; CELL CULTURE; CYTOLOGY; DERMIS; DIFFUSE SCLERODERMA; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; LIMITED SCLERODERMA; METABOLISM; MICROVASCULATURE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SKIN; VASCULARIZATION;

ADULT; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; DERMIS; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; INTERLEUKIN-1BETA; MALE; MICROVESSELS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84990882898     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39817     Document Type: Article

References (35)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989–2003.
2. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015;6:272.
3. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255–63.
4. Kahaleh MB, Osborn I, Leroy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982;96:610–3.
5. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007;19:574–9.
6. Solanilla A, Villeneuve J, Auguste P, Hugues M, Alioum A, Lepreux S, et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009;48:1036–44.
7. Chiang TM, Takayama H, Postlethwaite AE. Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis. Thromb Res 2006;117:299–306.
8. Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG, et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 2012;45:584–7.
9. Van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014;370:433–43.
10. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961–72.
11. Hillen MR, Radstake TR, Hack CE, van Roon JA. Thymic stromal lymphopoietin as a novel mediator amplifying immunopathology in rheumatic disease. Rheumatology (Oxford) 2015;54:1771–9.
12. Lo Kuan E, Ziegler SF. Thymic stromal lymphopoietin and cancer. J Immunol 2014;193:4283–8.
13. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005;202:1213–23.
14. Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011;208:479–90.
15. Datta A, Alexander R, Sulikowski MG, Nicholson AG, Maher TM, Scotton CJ, et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol 2013;191:4867–79.
16. Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, et al. Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor β. Arthritis Rheum 2013;65:1335–46.
17. Usategui A, Criado G, Izquierdo E, del Rey MJ, Carreira PE, Ortiz P, et al. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis. Ann Rheum Dis 2013;72:2018–23.
18. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
19. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
20. Truchetet ME, Brembilla NC, Montanari E, Lonati P, Raschi E, Zeni S, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013;65:1347–56.
21. Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 2013;15:R151.
22. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010;107:252–7.
23. Le QT, Gomez G, Zhao W, Hu J, Xia HZ, Fukuoka Y, et al. Processing of human protryptase in mast cells involves cathepsins L, B, and C. J Immunol 2011;187:1912–8.
24. Loppnow H, Bil R, Hirt S, Schonbeck U, Herzberg M, Werdan K, et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998;91:134–41.
25. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015;125:2795–807.
26. Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, et al. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 2014;6:232ra50.
27. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028–40.
28. Manetti M. Deciphering the alternatively activated (M2) phenotype of macrophages in scleroderma. Exp Dermatol 2015;24:576–8.
29. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673–80.
30. H-17 responses. Nat Immunol 2008;9:650–7.
31. Zhou B, Comeau MR, de Smedt T, Liggitt HD, Dahl ME, Lewis DB, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 2005;6:1047–53.
32. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012;8:534–42.
33. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Platelet-mediated modulation of adaptive immunity: a communication link between innate and adaptive immune compartments. Immunity 2003;19:9–19.
34. Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, et al. Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010;2:47ra63.
35. Kowal-Bielecka O, Kowal K, Lewszuk A, Bodzenta-Lukaszyk A, Walecki J, Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005;64:484–6.